Global Targeted Drug ALK Inhibitors for NSCLC Market Research Report 2025

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Crizotinib
1.2.3 Ceritinib
1.2.4 Alectinib
1.2.5 Brigatinib
1.2.6 Lorlatinib
1.2.7 Others
1.3 Market by Application
1.3.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Perspective (2020-2031)
2.2 Global Targeted Drug ALK Inhibitors for NSCLC Growth Trends by Region
2.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Region (2020-2025)
2.2.3 Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Region (2026-2031)
2.3 Targeted Drug ALK Inhibitors for NSCLC Market Dynamics
2.3.1 Targeted Drug ALK Inhibitors for NSCLC Industry Trends
2.3.2 Targeted Drug ALK Inhibitors for NSCLC Market Drivers
2.3.3 Targeted Drug ALK Inhibitors for NSCLC Market Challenges
2.3.4 Targeted Drug ALK Inhibitors for NSCLC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Revenue (2020-2025)
3.1.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Players (2020-2025)
3.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Targeted Drug ALK Inhibitors for NSCLC Revenue
3.4 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2024
3.5 Global Key Players of Targeted Drug ALK Inhibitors for NSCLC Head office and Area Served
3.6 Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Product and Application
3.7 Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drug ALK Inhibitors for NSCLC Breakdown Data by Type
4.1 Global Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Type (2020-2025)
4.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Type (2026-2031)
5 Targeted Drug ALK Inhibitors for NSCLC Breakdown Data by Application
5.1 Global Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Application (2020-2025)
5.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
6.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
6.4 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
7.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
7.4 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
8.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025)
8.4 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
9.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
9.4 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
10.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
10.4 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Introduction
11.1.4 Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Introduction
11.2.4 Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
11.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
11.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview
11.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Introduction
11.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Development
11.4 ARIAD Pharmaceuticals (Takeda)
11.4.1 ARIAD Pharmaceuticals (Takeda) Company Details
11.4.2 ARIAD Pharmaceuticals (Takeda) Business Overview
11.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Introduction
11.4.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.4.5 ARIAD Pharmaceuticals (Takeda) Recent Development
11.5 Genvio Pharma Limited
11.5.1 Genvio Pharma Limited Company Details
11.5.2 Genvio Pharma Limited Business Overview
11.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
11.5.4 Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.5.5 Genvio Pharma Limited Recent Development
11.6 Beacon Pharma Limited
11.6.1 Beacon Pharma Limited Company Details
11.6.2 Beacon Pharma Limited Business Overview
11.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
11.6.4 Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.6.5 Beacon Pharma Limited Recent Development
11.7 Drug International Limted
11.7.1 Drug International Limted Company Details
11.7.2 Drug International Limted Business Overview
11.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Introduction
11.7.4 Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.7.5 Drug International Limted Recent Development
11.8 Incepta Pharmaceuticals
11.8.1 Incepta Pharmaceuticals Company Details
11.8.2 Incepta Pharmaceuticals Business Overview
11.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Introduction
11.8.4 Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.8.5 Incepta Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Crizotinib
Table 3. Key Players of Ceritinib
Table 4. Key Players of Alectinib
Table 5. Key Players of Brigatinib
Table 6. Key Players of Lorlatinib
Table 7. Key Players of Others
Table 8. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2020-2025)
Table 12. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2026-2031)
Table 14. Targeted Drug ALK Inhibitors for NSCLC Market Trends
Table 15. Targeted Drug ALK Inhibitors for NSCLC Market Drivers
Table 16. Targeted Drug ALK Inhibitors for NSCLC Market Challenges
Table 17. Targeted Drug ALK Inhibitors for NSCLC Market Restraints
Table 18. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Players (2020-2025)
Table 20. Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2024)
Table 21. Ranking of Global Top Targeted Drug ALK Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Headquarters and Area Served
Table 24. Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Product and Application
Table 25. Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type (2020-2025)
Table 29. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type (2026-2031)
Table 31. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application (2020-2025)
Table 33. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application (2026-2031)
Table 35. North America Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 50. Pfizer Company Details
Table 51. Pfizer Business Overview
Table 52. Pfizer Targeted Drug ALK Inhibitors for NSCLC Product
Table 53. Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 54. Pfizer Recent Development
Table 55. Novartis Company Details
Table 56. Novartis Business Overview
Table 57. Novartis Targeted Drug ALK Inhibitors for NSCLC Product
Table 58. Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 59. Novartis Recent Development
Table 60. Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
Table 61. Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview
Table 62. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product
Table 63. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 64. Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Development
Table 65. ARIAD Pharmaceuticals (Takeda) Company Details
Table 66. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 67. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product
Table 68. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 69. ARIAD Pharmaceuticals (Takeda) Recent Development
Table 70. Genvio Pharma Limited Company Details
Table 71. Genvio Pharma Limited Business Overview
Table 72. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product
Table 73. Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 74. Genvio Pharma Limited Recent Development
Table 75. Beacon Pharma Limited Company Details
Table 76. Beacon Pharma Limited Business Overview
Table 77. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product
Table 78. Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 79. Beacon Pharma Limited Recent Development
Table 80. Drug International Limted Company Details
Table 81. Drug International Limted Business Overview
Table 82. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product
Table 83. Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 84. Drug International Limted Recent Development
Table 85. Incepta Pharmaceuticals Company Details
Table 86. Incepta Pharmaceuticals Business Overview
Table 87. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product
Table 88. Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 89. Incepta Pharmaceuticals Recent Development
Table 90. Research Programs/Design for This Report
Table 91. Key Data Information from Secondary Sources
Table 92. Key Data Information from Primary Sources
Table 93. Authors List of This Report


List of Figures
Figure 1. Targeted Drug ALK Inhibitors for NSCLC Picture
Figure 2. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Type: 2024 VS 2031
Figure 4. Crizotinib Features
Figure 5. Ceritinib Features
Figure 6. Alectinib Features
Figure 7. Brigatinib Features
Figure 8. Lorlatinib Features
Figure 9. Others Features
Figure 10. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Application: 2024 VS 2031
Figure 12. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 13. Adenocarcinoma of NSCLC Case Studies
Figure 14. Large Cell Carcinoma of NSCLC Case Studies
Figure 15. Targeted Drug ALK Inhibitors for NSCLC Report Years Considered
Figure 16. Global Targeted Drug ALK Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Targeted Drug ALK Inhibitors for NSCLC Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region: 2024 VS 2031
Figure 19. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Players in 2024
Figure 20. Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2024
Figure 22. North America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Targeted Drug ALK Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 24. United States Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Targeted Drug ALK Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 28. Germany Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2020-2031)
Figure 36. China Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 44. Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 48. Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Pfizer Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
Figure 52. Novartis Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
Figure 53. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
Figure 54. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
Figure 55. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
Figure 56. Beacon Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
Figure 57. Drug International Limted Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
Figure 58. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit